Pfizer Inc. (NYSE:PFE) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $36.83 and last traded at $36.70, with a volume of 12,815,228 shares trading hands. The stock had previously closed at $36.31.

PFE has been the subject of a number of research reports. Piper Jaffray Cos. restated an “overweight” rating and issued a $54.00 price target on shares of Pfizer in a research report on Sunday, March 20th. S&P Equity Research restated a “buy” rating on shares of Pfizer in a research report on Tuesday, April 12th. Sanford C. Bernstein restated a “buy” rating and issued a $36.00 price target on shares of Pfizer in a research report on Tuesday, April 5th. Bank of America Corp. restated a “buy” rating and issued a $28.25 price target (down previously from $38.48) on shares of Pfizer in a research report on Tuesday, May 10th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Friday, May 6th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Pfizer has a consensus rating of “Buy” and a consensus price target of $38.08.

The firm has a 50-day moving average price of $35.00 and a 200 day moving average price of $32.17. The company has a market capitalization of $222.43 billion and a P/E ratio of 30.061.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.12. During the same quarter in the prior year, the company earned $0.51 EPS. The business had revenue of $13 billion for the quarter, compared to the consensus estimate of $12 billion. Pfizer’s revenue was up 19.3% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post $2.44 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Friday, August 5th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Wednesday, August 3rd. This represents a $1.20 annualized dividend and a yield of 3.30%.

In other news, EVP Frank A. Damelio sold 100,000 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $34.49, for a total value of $3,449,000.00. Following the sale, the executive vice president now directly owns 472,994 shares of the company’s stock, valued at $16,313,563.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Loretta V. Cangialosi sold 86,000 shares of the stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $33.97, for a total value of $2,921,420.00. Following the completion of the sale, the vice president now directly owns 271,663 shares in the company, valued at $9,228,392.11. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently bought and sold shares of the company. San Francisco Sentry Investment Group CA increased its position in Pfizer by 0.4% in the fourth quarter. San Francisco Sentry Investment Group CA now owns 32,934 shares of the biopharmaceutical company’s stock worth $1,063,000 after buying an additional 125 shares in the last quarter. Jackson Wealth Management LLC increased its position in Pfizer by 0.4% in the fourth quarter. Jackson Wealth Management LLC now owns 51,115 shares of the biopharmaceutical company’s stock valued at $1,585,000 after buying an additional 214 shares during the period. Rowland & Co. Investment Counsel ADV increased its position in Pfizer by 0.6% in the fourth quarter. Rowland & Co. Investment Counsel ADV now owns 60,161 shares of the biopharmaceutical company’s stock valued at $1,907,000 after buying an additional 358 shares during the period. Retirement Design & Management Inc. ADV increased its position in Pfizer by 1.0% in the fourth quarter. Retirement Design & Management Inc. ADV now owns 37,930 shares of the biopharmaceutical company’s stock valued at $1,224,000 after buying an additional 379 shares during the period. Finally, Bollard Group LLC increased its position in Pfizer by 0.7% in the fourth quarter. Bollard Group LLC now owns 64,462 shares of the biopharmaceutical company’s stock valued at $2,081,000 after buying an additional 421 shares during the period.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.